Literature DB >> 31659730

Acute Pulmonary Exacerbations in Cystic Fibrosis.

Christopher H Goss1,2.   

Abstract

With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2019        PMID: 31659730     DOI: 10.1055/s-0039-1697975

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  12 in total

1.  Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.

Authors:  Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes
Journal:  Respir Med       Date:  2021-11-23       Impact factor: 3.415

2.  A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.

Authors:  Christopher H Goss; Sonya L Heltshe; Natalie E West; Michelle Skalland; Don B Sanders; Raksha Jain; Tara L Barto; Barbra Fogarty; Bruce C Marshall; Donald R VanDevanter; Patrick A Flume
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

3.  C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.

Authors:  D R VanDevanter; S L Heltshe; M Skalland; N E West; D B Sanders; C H Goss; P A Flume
Journal:  J Cyst Fibros       Date:  2021-12-18       Impact factor: 5.527

4.  Lung Ultrasound in Children with Cystic Fibrosis in Comparison with Chest Computed Tomography: A Feasibility Study.

Authors:  Ioana Mihaiela Ciuca; Liviu Laurentiu Pop; Mihaela Dediu; Emil Robert Stoicescu; Monica Steluta Marc; Aniko Maria Manea; Diana Luminita Manolescu
Journal:  Diagnostics (Basel)       Date:  2022-02-01

Review 5.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

6.  Impact of newborn screening for cystic fibrosis on clinical outcomes of pediatric patients: 10 years' experience in Lodz Voivodship.

Authors:  M Olszowiec-Chlebna; E Mospinek; J Jerzynska
Journal:  Ital J Pediatr       Date:  2021-04-09       Impact factor: 2.638

Review 7.  Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives.

Authors:  Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli
Journal:  Antibiotics (Basel)       Date:  2021-03-22

8.  Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis.

Authors:  Elena Fernández Fernández; Mary Joyce; Andrew O'Sullivan; Ronan MacLoughlin
Journal:  Antibiotics (Basel)       Date:  2021-04-21

Review 9.  Fungal Infection and Inflammation in Cystic Fibrosis.

Authors:  T Spencer Poore; Gina Hong; Edith T Zemanick
Journal:  Pathogens       Date:  2021-05-18

10.  A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.

Authors:  Edward F Nash; Jocelyn Choyce; Victoria Carrolan; Edwin Justice; Karen L Shaw; Alice Sitch; Hema Mistry; Joanna L Whitehouse
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.